Abstract
The transforming growth factor-β (TGF-β) signaling pathway is associated with carcinogenesis and various biological processes. SMAD2 and SMAD4, which are putative tumor suppressors, have an important role in TGF-β signaling. The aberrant expression of these genes is implicated in some cancers. However, the mechanisms of SMAD2 and SMAD4 dysregulation are poorly understood. In this study, we observed that miR-27a was upregulated in lung cancer cell lines and patients. In addition, SMAD2 and SMAD4 genes were identified as targets of miR-27a by several target prediction databases and experimental validation. Functional studies revealed that miR-27a overexpression decreased SMAD2 and SMAD4 mRNA and protein levels. Furthermore, miR-27a contributed to cell proliferation and invasion by inhibiting TGF-β-induced cell cycle arrest. These results suggest that miR-27a may function as an oncogene by regulating SMAD2 and SMAD4 in lung cancer. Thus, miR-27a may be a potential target for cancer therapy.
Original language | English |
---|---|
Pages (from-to) | 1992-1998 |
Number of pages | 7 |
Journal | Molecular Carcinogenesis |
Volume | 56 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2017 |
Bibliographical note
Publisher Copyright:© 2017 Wiley Periodicals, Inc.
Keywords
- SMAD2
- SMAD4
- TGF-β
- lung cancer
- miR-27a